Odonate Therapeutics, Inc. Restructuring and Related Cost, Expected Cost
Odonate Therapeutics, Inc. had Restructuring and Related Cost, Expected Cost of $11.60 million as of 2021-03-31, per its 10-Q filed 2021-11-10.
Discontinued › Notes
us-gaap:RestructuringAndRelatedCostExpectedCost1 · last filed 2021-11-10
- 2021-03-31: Restructuring and Related Cost, Expected Cost $11.60M; Restructuring and Related Cost, Expected Cost as first filed $12.00M.
| Period end | Restructuring and Related Cost, Expected Cost | Restructuring and Related Cost, Expected Cost as first filed |
|---|---|---|
| 2021-03-31 | $11.60M 10-Q · filed 2021-11-10 | $12.00M 10-Q · filed 2021-05-14 |